JP2020517665A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517665A5
JP2020517665A5 JP2019557488A JP2019557488A JP2020517665A5 JP 2020517665 A5 JP2020517665 A5 JP 2020517665A5 JP 2019557488 A JP2019557488 A JP 2019557488A JP 2019557488 A JP2019557488 A JP 2019557488A JP 2020517665 A5 JP2020517665 A5 JP 2020517665A5
Authority
JP
Japan
Prior art keywords
less
refitrimod
sclc
tlr
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019557488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517665A (ja
Filing date
Publication date
Priority claimed from EP17000678.7A external-priority patent/EP3392345A1/en
Application filed filed Critical
Publication of JP2020517665A publication Critical patent/JP2020517665A/ja
Publication of JP2020517665A5 publication Critical patent/JP2020517665A5/ja
Pending legal-status Critical Current

Links

JP2019557488A 2017-04-22 2018-04-23 小細胞肺がん治療のためのバイオマーカー Pending JP2020517665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17000678.7 2017-04-22
EP17000678.7A EP3392345A1 (en) 2017-04-22 2017-04-22 Biomarker for small cell lung cancer therapy
PCT/EP2018/060377 WO2018193137A1 (en) 2017-04-22 2018-04-23 Biomarker for small cell lung cancer therapy

Publications (2)

Publication Number Publication Date
JP2020517665A JP2020517665A (ja) 2020-06-18
JP2020517665A5 true JP2020517665A5 (enExample) 2021-05-27

Family

ID=58668698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557488A Pending JP2020517665A (ja) 2017-04-22 2018-04-23 小細胞肺がん治療のためのバイオマーカー

Country Status (6)

Country Link
US (1) US20200385732A1 (enExample)
EP (2) EP3392345A1 (enExample)
JP (1) JP2020517665A (enExample)
CN (1) CN110914428A (enExample)
TW (1) TW201843451A (enExample)
WO (1) WO2018193137A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
EP4104830A1 (en) * 2021-06-16 2022-12-21 Burghardt Wittig Sequential innate and adaptive immune modulation for cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
WO2004041183A2 (en) * 2002-11-01 2004-05-21 The Regents Of The University Of California Methods of treating pulmonary fibrotic disorders
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
CN103260415A (zh) * 2010-03-05 2013-08-21 铂雅制药公司 治疗小细胞肺癌的方法
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
WO2016040167A1 (en) * 2014-09-08 2016-03-17 Brandon Higgs Compositions and methods for detecting and treating small cell lung cancer
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides

Similar Documents

Publication Publication Date Title
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
JP2021063088A5 (enExample)
JP2013501224A5 (enExample)
JP2010529999A5 (enExample)
JP2016518387A5 (enExample)
JP2023548055A5 (enExample)
ATE516285T1 (de) Dihydropyridinonderivate
RU2017134443A (ru) Способ лечения с применением традипитанта
RU2016110874A (ru) Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
JP2016530291A5 (enExample)
CN111989095A (zh) 预防或治疗肿瘤疗法副作用的方法
WO2019157056A8 (en) Treatment of patients with classic fabry disease
JP2016515623A5 (enExample)
JP2023531675A5 (enExample)
JP2015510882A5 (enExample)
JP2021529829A5 (enExample)
JP2015522603A5 (enExample)
JP2016512817A5 (enExample)
JP2010500284A5 (enExample)
JP2013528649A5 (enExample)
JP2018506533A5 (enExample)
JP2019513138A5 (enExample)
Winslet et al. The influence of age on the surgical management of carcinoma ofthe stomach
JP2015521598A5 (enExample)